Re:Goldman Sachs questions whether curing patients is a sust...
by chestervonwinch on Friday April 13, 2018 @07:30AM
(#16828949)
OTOH, academia is supposed to be this type of meritocratic, results-driven ideal, and look where we are there. I suppose this a consequence of the measure that we use to "judge results". Do we start assigning healthcare R&D companies an "impact factor"? I know the journal impact factor is a bad example since it is criticized for being gameable, but I'm just using it to convey what I mean.
[ Parent
| on HN ]
There are no comments on this comment yet.